OBJECTIVES: To determine concentrations of adiponectin and its predictive value on outcome in a cohort of patients with congestive heart failure (CHF). METHODS: Serum and clinical data were obtained for outpatients with clinically controlled CHF (n = 175). Serum concentrations of adiponectin, C reactive protein, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin (IL) -1beta, IL-6, IL-8, IL-10, IL-12, tumour necrosis factor alpha and CD-40 ligand were determined. The association of adiponectin with the clinical severity of CHF was sought as well as the predictive value of this adipokine on mortality, CHF hospitalisations or the occurrence of each of these end points. RESULTS: Concentrations of adiponectin were significantly increased in patients with CHF. Patients with higher New York Heart Association class had significantly higher serum concentrations of adiponectin. Adiponectin serum concentrations were lower in patients with diabetes and CHF as well as in patients with ischaemic cardiomyopathy. Serum adiponectin concentration was positively associated with age and NT-proBNP but was negatively correlated with C reactive protein concentrations. Serum adiponectin above the 75th centile was found to be an independent predictor of total mortality, CHF hospitalisations or a composite of these end points over a two-year prospective follow up. CONCLUSION: Adiponectin is increased in CHF patients and predicts mortality and morbidity.
OBJECTIVES: To determine concentrations of adiponectin and its predictive value on outcome in a cohort of patients with congestive heart failure (CHF). METHODS: Serum and clinical data were obtained for outpatients with clinically controlled CHF (n = 175). Serum concentrations of adiponectin, C reactive protein, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin (IL) -1beta, IL-6, IL-8, IL-10, IL-12, tumour necrosis factor alpha and CD-40 ligand were determined. The association of adiponectin with the clinical severity of CHF was sought as well as the predictive value of this adipokine on mortality, CHF hospitalisations or the occurrence of each of these end points. RESULTS: Concentrations of adiponectin were significantly increased in patients with CHF. Patients with higher New York Heart Association class had significantly higher serum concentrations of adiponectin. Adiponectin serum concentrations were lower in patients with diabetes and CHF as well as in patients with ischaemic cardiomyopathy. Serum adiponectin concentration was positively associated with age and NT-proBNP but was negatively correlated with C reactive protein concentrations. Serum adiponectin above the 75th centile was found to be an independent predictor of total mortality, CHF hospitalisations or a composite of these end points over a two-year prospective follow up. CONCLUSION:Adiponectin is increased in CHFpatients and predicts mortality and morbidity.
Authors: K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 2000-06 Impact factor: 8.311
Authors: Stefan Engeli; Mareike Feldpausch; Kerstin Gorzelniak; Frauke Hartwig; Ute Heintze; Jürgen Janke; Matthias Möhlig; Andreas F H Pfeiffer; Friedrich C Luft; Arya M Sharma Journal: Diabetes Date: 2003-04 Impact factor: 9.461
Authors: N Ouchi; S Kihara; Y Arita; K Maeda; H Kuriyama; Y Okamoto; K Hotta; M Nishida; M Takahashi; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa Journal: Circulation Date: 1999 Dec 21-28 Impact factor: 29.690
Authors: C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Karen M O'Shea; David J Chess; Ramzi J Khairallah; Sharad Rastogi; Peter A Hecker; Hani N Sabbah; Kenneth Walsh; William C Stanley Journal: Am J Physiol Heart Circ Physiol Date: 2010-03-26 Impact factor: 4.733
Authors: W H Wilson Tang; Kevin Shrestha; Wilson Tong; Zeneng Wang; Richard W Troughton; Allen G Borowski; Allan L Klein; Stanley L Hazen Journal: Transl Res Date: 2013-03-13 Impact factor: 7.012